Alt5 Sigma Corporation Sets Record Date for Alyea Therapeutics Separation, Announces Leadership Details

Reuters

05-31

Alt5 Sigma Corporation Sets Record Date for Alyea <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Separation, Announces Leadership Details

Alt5 Sigma Corporation has announced a significant update regarding its planned transaction involving the separation of its healthcare assets, Alyea Therapeutics Corporation. Scheduled for May 21, 2025, the company confirmed that the record date for this transaction would be June 2, 2025. The transaction will involve a partial or full disposition of Alt5 Sigma's interests in Alyea, with further details regarding the method of transaction, such as a split-off or spin-off, to be disclosed at a later date. This follows Alt5 Sigma's earlier disclosure and confirms key leadership appointments within Alyea, including Amol Soin, M.D., as the prospective Chief Executive Officer and Director.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alt5 Sigma Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-25-028621), on May 30, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2539208691"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2539208691\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2539208691?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-31 04:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2539208691","market":"us","top_or_hot":-1,"title":"Alt5 Sigma Corporation Sets Record Date for Alyea Therapeutics Separation, Announces Leadership Details","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Alt5 Sigma Corporation Sets Record Date for Alyea <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Separation, Announces Leadership Details\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Alt5 Sigma Corporation has announced a significant update regarding its planned transaction involving the separation of its healthcare assets, Alyea Therapeutics Corporation. Scheduled for May 21, 2025, the company confirmed that the record date for this transaction would be June 2, 2025. The transaction will involve a partial or full disposition of Alt5 Sigma's interests in Alyea, with further details regarding the method of transaction, such as a split-off or spin-off, to be disclosed at a later date. This follows Alt5 Sigma's earlier disclosure and confirms key leadership appointments within Alyea, including Amol Soin, M.D., as the prospective Chief Executive Officer and Director.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alt5 Sigma Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-25-028621), on May 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alt5 Sigma Corporation Sets Record Date for Alyea Therapeutics Separation, Announces Leadership Details</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlt5 Sigma Corporation Sets Record Date for Alyea Therapeutics Separation, Announces Leadership Details\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-31 04:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Alt5 Sigma Corporation Sets Record Date for Alyea <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Separation, Announces Leadership Details\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Alt5 Sigma Corporation has announced a significant update regarding its planned transaction involving the separation of its healthcare assets, Alyea Therapeutics Corporation. Scheduled for May 21, 2025, the company confirmed that the record date for this transaction would be June 2, 2025. The transaction will involve a partial or full disposition of Alt5 Sigma's interests in Alyea, with further details regarding the method of transaction, such as a split-off or spin-off, to be disclosed at a later date. This follows Alt5 Sigma's earlier disclosure and confirms key leadership appointments within Alyea, including Amol Soin, M.D., as the prospective Chief Executive Officer and Director.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alt5 Sigma Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-25-028621), on May 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nNDL8DYBQX:1","article_id":"2539208691","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2539208691","pubTimestamp":1748637529,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Alt5 Sigma Corporation has announced a significant update regarding its planned transaction involving the separation of its healthcare assets, Alyea Therapeutics Corporation. Scheduled for May 21, 2025, the company confirmed that the record date for this transaction would be June 2, 2025. The transaction will involve a partial or full disposition of Alt5 Sigma's interests in Alyea, with further details regarding the method of transaction, such as a split-off or spin-off, to be disclosed at a later date. This follows Alt5 Sigma's earlier disclosure and confirms key leadership appointments within Alyea, including Amol Soin, M.D., as the prospective Chief Executive Officer and Director.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alt5 ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","ALTS":"PROSHARES MORNINGSTAR ALTERNATIVES SOLUTION ETF"},"translate_title":"Alt5 Sigma Corporation为Alyea Therapeutics分离设定了创纪录的日期，并宣布了领导层细节","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALTS":0.9},"content_text":"Alt5 Sigma Corporation Sets Record Date for Alyea Therapeutics Separation, Announces Leadership Details\n    \n\n        Alt5 Sigma Corporation has announced a significant update regarding its planned transaction involving the separation of its healthcare assets, Alyea Therapeutics Corporation. Scheduled for May 21, 2025, the company confirmed that the record date for this transaction would be June 2, 2025. The transaction will involve a partial or full disposition of Alt5 Sigma's interests in Alyea, with further details regarding the method of transaction, such as a split-off or spin-off, to be disclosed at a later date. This follows Alt5 Sigma's earlier disclosure and confirms key leadership appointments within Alyea, including Amol Soin, M.D., as the prospective Chief Executive Officer and Director.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alt5 Sigma Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-25-028621), on May 30, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"executive,event","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}